Tenet Healthcare Corporation

Valuation Analysis

About the Company

Tenet Healthcare Corporation en bref

Tenet Healthcare Corporation (THC) is currently trading at 150,38 € with a market capitalization of 13,0 Md €. The trailing P/E ratio stands at 8.97x, with a forward P/E of 9.73x. The 52-week range spans from 127,80 € to 215,51 €; the current price is 30.2% below the yearly high. Year-over-year revenue growth stands at +2.8%. The net profit margin stands at 7.94%.

💰 Dividende

Tenet Healthcare Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

21 analystes évaluent Tenet Healthcare Corporation (THC) au consensus : Achat Fort. L'objectif de cours moyen est de 212,38 €, soit un potentiel de +41.23% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 183,07 € à 251,07 €.

Tenet Healthcare Corporation : la thèse d'investissement en détail

Tenet Healthcare Corporation (THC) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 87.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 41.26% gross margin and 17.94% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Return on equity of 30.29% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Revenue growth has slowed to just 2.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valorisation en contexte

At a PEG of 4.53, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 6.49x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The analyst consensus price target implies 41.23% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility, higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Tenet Healthcare Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.